Mean platelet volume play a role in disease severity in patients with obstructive sleep apnea syndrome?

Abstract

Objectives: This study aims to show the effects of nasal continuous positive airway pressure CPAP treatment on platelet activation in patients with severe obstructive sleep apnea syndrome OSAS . Patients and Methods: Forty-six patients 29 males, 17 females; mean age 48.2±7.6 years; range 40 to 56 years with severe OSAS with apnea/hypopnea index AHI ≥30 were included in this study. Complete blood counts were analyzed and mean platelet volume MPV values were compared in patients before and after CPAP treatment at six months. Results: The mean MPV values before CPAP were 8.9±1.3 p<0.001 , while the mean values were 7.7±1.1 p<0.001 at six months after CPAP treatment in patients with severe OSAS. There was a statistically significant decrease in the MPV values after CPAP treatment. Patients’ number of platelets which was measured six months after the CPAP treatment increased at a significant level compared to baseline p<0.001 . Conclusion: Continuous positive airway pressure treatment caused a significant decrease in the MPV values in patients with severe OSAS. As a negative acute phase reactant, MPV can be used as a marker to exert the cardioprotective effect of CPAP.

Keywords

• Cardiovascular risk, continuous positive airway pressure, mean platelet volume, obstructive sleep apnea syndrome

Tıkayıcı uyku apne sendromunda ortalama trombosit hacminin hastalık şiddetinde rolü var mıdır?

Abstract

Amaç: Bu çalışmada, ağır tıkayıcı uyku apnesi sendromlu hastalarda TUAS kullanılan sürekli pozitif hava yolu basıncı CPAP tedavisinin trombosit aktivitesi üzerindeki etkisi gösterildi.Hastalar ve Yöntemler: Bu çalışmaya apne/hipopne indeksi AHİ ≥30 olan şiddetli TUAS’lı 46 hasta 29 erkek, 17 kadın; ort. yaş 48.2±7.6 yıl; dağılım 40-56 yıl alındı. Hastaların CPAP tedavisi öncesi ve sonrası altıncı ayda tam kan sayımları ölçüldü ve ortalama trombosit hacim OTH değerleri karşılaştırıldı.Bulgular: Şiddetli TUAS’lı hastaların CPAP öncesi OTH değerleri ortalama 8.9±1.3 p

Keywords

• Kardiyovasküler risk, sürekli pozitif hava yolu basıncı, ortalama trombosit hacmi, tıkayıcı uyku apne sendromu

References

1. Varol E, Ozturk O, Yucel H, Gonca T, Has M, Dogan A, et al. The effects of continuous positive airway pressure therapy on mean platelet volume in patients with obstructive sleep apnea. Platelets 2011;22:552-6.
2. Ulasli SS, Ozyurek BA, Yilmaz EB, Ulubay G. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Med Wewn 2012;122:284-90.
3. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008;5:136-43.
4. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 2003;41:1429-37.
5. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost 2003;9:177-90.
6. Sandhaus LM, Meyer P. How useful are CBC and reticulocyte reports to clinicians? Am J Clin Pathol 2002;118:787-93.
7. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96:776-81.
8. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 2008;75:291-4.

9. Bansal R, Gupta HL, Goel A, Yadav M. Association of increased platelet volume in patients of chronic obstructive pulmonary disease: clinical implications. J Indian Acad Clin Med 2002;3:169-72.
10. Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004;15:475-8.
11. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 2009;63:1509-15.
12. Ziegler MG, Nelesen R, Mills P, Ancoli-Israel S, Kennedy B, Dimsdale JE. Sleep apnea, norepinephrine-release rate, and daytime hypertension. Sleep 1997;20:224-31.
13. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995;96:1897-904.
14. Inancli HM, Enoz M. Obstructive sleep apnea syndrome and upper airway inflammation. Recent Pat Inflamm Allergy Drug Discov 2010;4:54-7.
15. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 2003;41:1429-37.
16. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53.